This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cubist Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

Cubist Pharmaceuticals (CBST)

Q2 2012 Earnings Call

July 19, 2012 5:00 pm ET

Executives

Eileen C. McIntyre - Senior Director of Investor Relations

Michael W. Bonney - Chief Executive Officer and Director

David W. J. McGirr - Chief Financial Officer, Principal Accounting Officer and Senior Vice President

Robert J. Perez - President and Chief Operating Officer

Steven C. Gilman - Chief Scientific Officer and Executive Vice President of Research & Development

Gregory Stea - Senior Vice President of Commercial Operations

Analysts

Mario V. Corso - Caris & Company, Inc., Research Division

Thomas J. Russo - Robert W. Baird & Co. Incorporated, Research Division

Eun K. Yang - Jefferies & Company, Inc., Research Division

Steve Byrne - BofA Merrill Lynch, Research Division

Alan Carr - Needham & Company, LLC, Research Division

Adnan S. Butt - RBC Capital Markets, LLC, Research Division

James F. Molloy - ThinkEquity LLC, Research Division

Howard Liang - Leerink Swann LLC, Research Division

Stephen Willey - Stifel, Nicolaus & Co., Inc., Research Division

Presentation

Operator

Good day. My name is Nikki, and I will be your events specialist today. At this time, I would like to welcome everyone to the Cubist Pharmaceuticals Second Quarter Earnings Call. [Operator Instructions] At this time, I would like to turn today's program over to Eileen McIntyre. Eileen, you may begin.

Eileen C. McIntyre

Good afternoon, and thank you for joining us for our review of Second Quarter 2012 Business Performance and Financial Results of Cubist Pharmaceuticals. Before introducing our speakers, I will read the safe harbor statement and describe the context for use of non-GAAP financial measures.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs